Early Detection of biomarkers in multiple cancers
The aim of the PAN cancer study is to evaluate the potential of Breath Biopsy to detect various types of cancer by profiling Volatile Organic Compounds (VOCs) on
The key parameter driving survival chances in patients with cancer is the stage at which the cancer is detected. Detection of cancer at its earliest stages, when it can be treated with curative intent, results in a dramatic improvement of survival rates whilst reducing treatment cost. Unfortunately, over half of
The PAN study is a collaborative effort between Cambridge University Hospital NHS Foundation Trust, University of Cambridge, Cancer Research UK (CRUK) and Owlstone Medical.
The PAN study will focus on seven cancer types and will initiate them over three staggered phases.
Subjects are currently being recruited from Cambridge University Hospitals by local research staff. Breath samples will be collected by means of the ReCIVA breath sampler which requires tidal breathing into a face mask for around 10 minutes. A
PAN is registered on the clinicaltrials.gov website under the identifier: NCT03756597
This study will be investigating subjects that have one of the selected cancer types and comparing them to a pool of control subjects.
Evaluating the potential of Breath Biopsy in the early detection of various types of cancer by profiling volatile organic compounds (VOCs) on breath.
Breath samples will be collected on-site using the ReCIVA breath sampler device and it's collection station. The samples will then be analysed at Owlstone Medical's central laboratory in Cambridge, UK.